SUNDAY, APRIL 15
1:15 p.m. to 3:15 p.m.
From Genes to Dreams: Translating Understanding of Biology into Cures of Pediatric Cancers
Co-Chairpersons: Richard J. Gilbertson, St. Jude Children’s Research Hospital, Memphis, TN, and Katherine K. Matthay, UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA
- From embryogenesis to tumorigenesis: Are pediatric brain tumors a consequence of abnormal development?, David H. Rowitch, Dana-Farber Cancer Institute, Boston, MA
- Acute leukemias: Dissecting a diseased genome, James R. Downing, St. Jude Children’s Hospital, Memphis, TN
- The science of surviving: Molecular and clinical insights to improving the long-term outcome of children with cancer, Smita Bhatia, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA
- Turning knowledge into know-how: Taking the neuroblastoma genome to the clinic, John M. Maris, Children’s Hospital of Philadelphia, Philadelphia, PA
SUNDAY, APRIL 15
3:15 p.m. to 5:15 p.m.
Sarcomas
Co-Chairpersons: Lee J. Helman, National Cancer Institute, Bethesda, MD, and George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
- Speakers and titles to be announced
MONDAY, APRIL 16
10:00 a.m. to 12:00 p.m.
Lung Cancer
Co-Chairpersons: Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, and Joan H. Schiller, UT Southwestern Medical Center, Dallas, TX
- Title to be announced, Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA
- Targeted therapy for lung cancer, Joan H. Schiller, UT Southwestern Medical Center, Dallas, TX
- Title to be announced, David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN
- Stem cells in normal lung and lung cancer, Carla Bender Kim, Harvard Medical School, Boston, MA
New Concepts in AML
Co-Chairpersons: James D. Griffin, Dana-Farber Cancer Institute, Boston, MA, and Christine Chomienne, Hôpital St. Louis, Paris, France
- Transcription factors, hemotopoietic stem cells, and cancer, Daniel G. Tenen, Harvard Institutes of Medicine, Boston, MA
- Leukemic stem cells: Getting to the root of AML, Dominique Bonnet, London Research Institute, London, United Kingdom
- Signal transduction pathways in AML, D. Gary Gilliland, Harvard Medical School, Boston, MA
MONDAY, APRIL 16
12:00 p.m. to 2:00 p.m.
Lymphoma
Co-Chairpersons: Riccardo Dalla-Favera, Columbia University, New York, NY, and Ronald Levy, Stanford University School of Medicine, Stanford, CA
- Molecular pathogenesis of B-cell lymphoma, Riccardo Dalla-Favera, Columbia University, New York, NY
- Immune therapy for lymphoma, Ronald Levy, Stanford University School of Medicine, Stanford, CA
- Title to be announced, Owen A. O’Connor, Memorial Sloan-Kettering Cancer Center, New York, NY
Recent Progress in Diagnosis and Management of Prostate Cancer
Co-Chairpersons: Owen N. Witte, Howard Hughes Medical Institute at UCLA, Los Angeles, CA, and Fritz H. Schröder, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
- How can we improve on PSA testing for prostate cancer?, Mark A. Rubin, Brigham and Women’s Hospital, Boston, MA
- How to diagnose prostate cancer in 2007? Can over treatment be avoided?, Laurence H. Klotz, Sunnybrook Health Sciences Center, Toronto, ON, Canada
- Progress identifying aggressive prostate cancer, Tomasz M. Beer, Oregon Health and Science University, Portland, OR
- Progress in the treatment of prostate cancer: Do new targets lead to clinical progress?, John T. Isaacs, Johns Hopkins Oncology Center, Baltimore, MD
MONDAY, APRIL 16
2:00 p.m. to 4:00 p.m.
Basal-like Breast Cancers: What We Know and Don’t Know
Co-Chairpersons: Olufunmilayo I. Olopade, University of Chicago Medical Center, Chicago, IL, and Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
- Designing rational treatments, Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
- Epidemiology and genetics, Olufunmilayo I. Olopade, University of Chicago Medical Center, Chicago, IL
- What’s happening on the X-chromosome?, Andrea L. Richardson, Brigham and Women’s Hospital, Boston, MA
- Chemoprevention in mouse models of breast cancer susceptibility, Jos Jonkers, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Renal Cancer
Co-Chairpersons: William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA, and Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA
- MT or pathway in RCC, George V. Thomas, University of California, Los Angeles, CA
- Abnormalities associated with hereditary renal cancer, W. Marston Linehan, National Cancer Institute, Bethesda, MD
- VHL pathway in RCC, William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA
- Current and future status of targeted therapy in RCC, Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA
MONDAY, APRIL 16
4:00 p.m. to 6:00 p.m.
Breast Cancer
Co-Chairpersons: Myles A. Brown, Dana-Farber Cancer Institute, Boston, MA, and Dennis J. Slamon, David Geffen School of Medicine at UCLA, Los Angeles, CA
- Speakers and titles to be announced
TUESDAY, APRIL 17
8:00 a.m. to 10:00 a.m.
Advances in Early Detection and Targeted Therapy of Ovarian Cancer
Co-Chairpersons: Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY, and Robert F. Ozols, Fox Chase Cancer Center, Philadelphia, PA
- Genetic models of ovarian cancer: Lessons learned and challenges ahead, Daniela M. Dinvlescu, Brigham and Women’s Hospital, Boston, MA
- Advances in risk assessment and early detection of ovarian cancer, Daniel W. Cramer, Brigham and Women’s Hospital, Boston, MA
- Molecular targeted therapeutic strategies in ovarian cancer, Russel J. Schilder, Fox Chase Cancer Center, Philadelphia, PA
- Vaccine therapy for ovarian cancer: Barriers and opportunities, Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY
Translational Research in GI/Esophageal Cancers: Bench, Bedside, and Population
Co-Chairpersons: Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA, and Timothy C. Wang, Columbia University Medical Center, New York, NY
- The etiology of gastric cancer: An update, Pelayo Correa, Vanderbilt University Medical Center, Nashville, TN
- Safe and effective cancer prevention in Barrett’s esophagus: How do we get there?, Patricia L. Blount, Fred Hutchinson Cancer Research Center, Seattle, WA
- Models of esophageal cancer, Anil K. Rustgi, University of Pennsylvania, Philadelphia, PA
- New directions in multi-modality therapy of locally advanced esophageal cancer, Arlene A. Forastiere, Johns Hopkins Oncology Center, Baltimore, MD
TUESDAY, APRIL 17
10:00 a.m. to 12:00 p.m.
Colorectal Cancer
Co-Chairpersons: Raju Kucherlapati, Harvard Medical School, Boston, MA, and Raymond N. DuBois, Vanderbilt-Ingram Cancer Center, Nashville, TN
- Targeting inflammatory mediators for cancer prevention, Raymond N. DuBois, Vanderbilt-Ingram Cancer Center, Nashville, TN
- Gastrointestinal cancer proteomics, Raju Kucherlapati, Harvard Medical School, Boston, MA
- Genetic interaction between Rpa1 and p53 in murine tumorigenesis, Winfried K. G. Edelmann, Cancer Research Center, Bronx, NY
- New implications of developmental disorders for colonic neoplasia, Benjamin G. Neel, Beth Israel Deaconess Medical Center, Boston, MA
Melanoma, Molecular Biology, and Targeted Therapy Translation
Co-Chairpersons: Richard M. Marais, The Institution of Cancer Research, London, United Kingdom, and Keith T. Flaherty, University of Pennsylvania, Philadelphia, PA
- Stress response programs in melanoma progression and chemoresistance, Maria Soengas, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
- New mouse models of BRAF- and NRAS-induced malignant melanoma, Martin McMahon, UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA
- MITF and regulation of growth of differentiation in melanocytes and melanoma, David E. Fisher, Harvard Medical School, Boston, MA
- Melanoma molecular biology and targeted therapy translation, Keith T. Flaherty, University of Pennsylvania, Philadelphia, PA
TUESDAY, APRIL 17
12:00 p.m. to 2:00 p.m.
Liver Cancer
Co-Chairpersons: Snorri S. Thorgeirsson, National Cancer Institute, Bethesda, MD, and Jack R. Wands, Massachusetts General Hospital Cancer Center, Providence, RI
- The art of liver cancer prognosis: From the view point of biology, Xin Wei Wang, National Cancer Institute, Bethesda, MD
- B-catenin pathway and human liver cancer, Jack R. Wands, Massachusetts General Hospital Cancer Center, Providence, RI
- Genetics of human hepatoblastoma, Marie-Annick Buendia, Institut Pasteur, Paris, France
- Genomic decoding of liver cancer, Snorri S. Thorgeirsson, National Cancer Institute, Bethesda, MD
Recent Advances in Head and Neck Cancer
Co-Chairpersons: Jennifer R. Grandis, University of Pittsburgh School of Medicine, Pittsburgh, PA, and Waun Ki Hong, UT M.D. Anderson Cancer Center, Houston, TX
- Overview of recent advances in head and neck cancer, Waun Ki Hong, UT M.D. Anderson Cancer Center, Houston, TX
- Genomics and proteomics, Christine H. Chung, Vanderbilt-Ingram Cancer Center, Nashville, TN
- Targeted therapy, Jennifer R. Grandis, University of Pittsburgh School of Medicine, Pittsburgh, PA
- Nasopharyngeal cancer, Anthony T. C. Chan, Chinese University of Hong Kong, Shatin, Hong Kong, China
TUESDAY, APRIL 17
2:00 p.m. to 4:00 p.m.
Malignant Gliomas
Co-Chairpersons: Webster K. Cavenee, Moores UCSD Cancer Center, La Jolla, CA, and W. K. Alfred Yung, UT M.D. Anderson Cancer Center, Houston, TX
- Animal models, Luis F. Parada, UT Southwestern Medical Center, Dallas, TX
- Brain tumor stem cells, Peter B. Dirks, Hospital for Sick Children, Toronto, ON, Canada
- Small molecule-based therapy for glioblastoma: Importance of genotype, Timothy Cloughesy, UCLA School of Medicine, Los Angeles, CA
- Antibody-based therapy for glioblastoma, Terrance G. Johns, Ludwig Institute for Cancer Research, Heidelberg, Germany
TUESDAY, APRIL 17
4:00 p.m. to 6:00 p.m.
Early Detection of Pancreatic Cancer: The Holy Grail
Co-Chairpersons: Nabeel H. Bardeesy, Massachusetts General Hospital, Boston, MA, and Margaret A. Tempero, University of California, San Francisco, CA
- Title to be announced, Matthias Hebrok, University of California, San Francisco, CA
- In-depth quantitative proteomics for pancreatic cancer biomarker discovery, Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA
- Title to be announced, Randall E. Brand, Evanston Northwestern Healthcare, Glenview, IL
- Pancreatic cancer-induced diabetes: A clue to its early diagnosis, Suresh T. Chari, Mayo Clinic College of Medicine, Rochester, MN
WEDNESDAY, APRIL 18
8:00 a.m. to 10:00 a.m.
Bladder Cancer
Co-Chairpersons: Cory Abate-Shen, UMDNJ-R.W. Johnson Medical School, Piscataway, NJ, and Michael A. O’Donnell, University of Iowa, Iowa City, IA
- Molecular pathways in bladder cancer: Defining mechanisms and therapeutic targets, Richard J. Cote, USC Norris Comprehensive Cancer Center, Los Angeles, CA
- How research into the immune mechanisms behind intrevesical BCG therapy is resulting in improvements in therapy for superficial bladder cancer, Michael A. O’Donnell, University of Iowa, Iowa City, IA
- A new mouse model of invasive bladder cancer, Cory Abate-Shen, UMDNJ-R.W. Johnson Medical School, Piscataway, NJ
- Mutation and expression of FGF receptors in bladder cancer: Novel targets for therapy in superficial and advanced disease?, Margaret Knowles, Cancer Research UK Clinical Centre, Leeds, United Kingdom
Myeloma
Co-Chairpersons: Sagar Loníal, Emory University Winship Cancer Institute, Atlanta, GA, and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
- PI3 1AKT pathway as a therapeutic target in myeloma, Sagar Lonial, Emory University Winship Cancer Institute, Atlanta, GA
- Rationale for proteasome inhibitor therapy alone and in combination in myeloma, Dharminder Chauhan, Dana-Farber Cancer Institute, Boston, MA
- Clinical trials of novel targeted therapies in myeloma, S. Vincent Rajkumar, Mayo Clinic and Foundation, Rochester, MN
- Novel insights in pathogenesis of bone disease in myeloma, Gregory R. Mundy, Vanderbilt Center of Bone Biology, Nashville, TN